{"id":"W3082899459","doi":"10.1016/s1470-2045(20)30443-5","title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":327,"is_retracted":false,"has_abstract":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"F. Hoffmann-La Roche; AbbVie","keywords":"Obinutuzumab; Chlorambucil; Venetoclax; Medicine; Internal medicine; Oncology; Chronic lymphocytic leukemia; Fludarabine; Open label; Clinical trial; Chemotherapy; Leukemia; Cyclophosphamide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00148085,0.001532519,0.002662885,0.0003866584,0.000415278,0.001413886,0.0009794747,0.001558324,0.005409391],"category_scores_gemma":[0.001987944,0.0004534794,0.002262603,0.0004651858,0.001117537,0.001204776,0.0004278537,0.003505845,0.0009871573],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001028983,"about_ca_system_score_gemma":0.0009469991,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001819495,"about_ca_topic_score_gemma":0.004128269,"domain_scores_codex":[0.9993609,0.000347679,0.00002363953,0.00009422802,0.00003810647,0.0001355254],"domain_scores_gemma":[0.9989544,0.0003760408,0.0002240392,0.00007618161,0.00004274354,0.0003266386],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9727518,0.002307646,0.0004513965,0.0005409778,0.0009708174,0.00003921522,0.00006544655,0.0003461227,0.001615592,0.000119805,0.0007176477,0.02007349],"study_design_scores_gemma":[0.9533328,0.04303278,0.001772502,0.00005847692,0.0004492271,0.00004312171,0.00003229987,0.0002498066,0.0002210573,0.000190349,0.0006029886,0.00001455597],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9842519,0.01040043,0.0004670409,0.0006932714,0.0006418373,0.000953879,0.0008021313,0.0001067421,0.001682734],"genre_scores_gemma":[0.9877821,0.004091765,0.0009764149,0.0008807236,0.000353008,0.001079498,0.001079184,0.00002980262,0.00372745],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005409391,"threshold_uncertainty_score":0.01809621,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2241489103395237,"score_gpt":0.4279868705273332,"score_spread":0.2038379601878094,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}